Sep 20, 2023 / 12:00PM GMT
Frank Mathias - Oxford Biomedica plc - CEO & Director
Good afternoon, everyone. Obviously, good morning to those on the other side of the ocean. Thank you for joining today's analyst briefing of our '23 interim results. It's a pleasure to speak to you today alongside with our Chief Financial Officer, Stuart Paynter, who many of you should know by now. And for the first time, our Chief Commercial Officer, Dr. Sebastien Ribault, who most of you will not met probably before. Sebastien, thank you for joining.
I will start by presenting our new strategy. Sebastien will provide a commercial update afterwards, and Stuart will follow with financial results for the first half of the year. After the presentation, we will open the room up for questions. We have a live webcast running. And for those joining us remotely, we will turn to you for any question after the presentation, and we'll also accept any written questions, which will be responded by our Investor Relations team following the presentation. Our clear company-wide goal is to create a why not the world leading quality and innovation-driven
Half Year 2023 Oxford Biomedica PLC Earnings Call Transcript
Sep 20, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers